Cullinan Therapeutics, Inc. (CGEM) stock
CGEMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$10.28+0.09 (+0.88%)
Close on Nov 13, 2026Market cap $661.57MP/E –Yield –
Cullinan Therapeutics price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Cullinan Therapeutics's price to book ratio was 1.9× on Apr 30, 2026, against 0.8× a year earlier. Over the last 5 years it ranged from 0.7× to 2.8×, with a median of 1.1×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Apr 30, 2026 | 1.9× | +0.6 |
| 2025 | Dec 31, 2025 | 1.4× | +0.2 |
| 2024 | Dec 31, 2024 | 1.1× | +0.2 |
| 2023 | Dec 29, 2023 | 0.9× | +0.1 |
| 2022 | Dec 30, 2022 | 0.8× | −0.7 |
| 2021 | Dec 31, 2021 | 1.5× | – |
See a number that looks wrong?